$ACHN Headlines Stocks trim Ukraine-inspired fall, post

New Post Public Reply Private Reply Replies (0) Message Board

Aug 18, 2014 at 9:44 AM

$ACHN Headlines

Stocks trim Ukraine-inspired fall, post weekly gain 4:08 p.m. Aug. 15, 2014 - Anora Mahmudova
In focus: New highs premature? 9:03 p.m. June 18, 2014 - Lawrence G. McMillan
Achillion shares up; FDA lifts hold on hepatitis C drug 10:25 a.m. June 10, 2014 - Anna Prior
U.S. stock futures sink on shutdown fears 8:38 a.m. Sept. 30, 2013 - Barbara Kollmeyer
Zynga shares rise, Achillion drops after hours 5:51 p.m. July 1, 2013 - Wallace Witkowski
FDA puts Achillion Hep C drug on clinical hold 5:16 p.m. July 1, 2013 - MarketWatch.com
Five stocks making moves 3:12 p.m. Feb. 14, 2013 - The Trading Deck
Thursday’s top gaining & declining stocks 5:02 p.m. Sept. 27, 2012 - Greg Morcroft
Achillion sees progress in hepatitis C study 9:04 a.m. Sept. 27, 2012 - MarketWatch.com
Vertex to advance testing of oral HCV drug regimen 10:34 a.m. Sept. 25, 2012 - Val Brickates Kennedy
Wednesday’s biggest gaining and declining stocks 4:37 p.m. Sept. 19, 2012 - MarketWatch
Achillion, Idenix move on price target changes 10:29 a.m. Sept. 19, 2012 - Val Brickates Kennedy
Gilead boosted as analysts hike price targets 10:42 a.m. Sept. 17, 2012 - Val Brickates Kennedy
Thursday’s biggest gaining and declining stocks 4:47 p.m. Aug. 16, 2012 - MarketWatch
Idenix plunges 30% on HCV drug setback 12:56 p.m. Aug. 16, 2012 - Val Brickates Kennedy
Bristol’s bad news is good for rivals: analysts 5:52 p.m. Aug. 2, 2012 - Val Brickates Kennedy
Gilead shares boosted by Bristol-Myers drug news 11:24 a.m. Aug. 2, 2012 - Val Brickates Kennedy
Bristol-Myers falls 7% on hepatitis C drug setback 10:09 a.m. Aug. 2, 2012 - Val Brickates Kennedy
Stocks to watch Thursday: Annie’s, Rite Aid 5:02 p.m. June 6, 2012 - David B. Wilkerson
Achillion's chief medical officer resigns 4:19 p.m. June 6, 2012 - Val Brickates Kennedy

Achillion Pharmaceuticals (ACHN) in Focus: Stock Up 9.6% - Tale of the Tape 59 min ago - Zacks.com
Top Analyst Upgrades and Downgrades: Achillion, GE, Monster, Newmont, SeaWorld and More 7:54 a.m. Today - 247WallSt.com
Deutsche Bank Raises Achillion Price Target 183% 7:28 a.m. Today - benzinga.com
Benzinga's Top #PreMarket Gainers 7:15 a.m. Today - benzinga.com
10 Analyst Stocks to Buy Under $10 With Massive Upside Calls 9:47 a.m. Aug. 16, 2014 - 247WallSt.com
Biotech Leader Gilead Sciences Scores Sovaldi Win 5:10 p.m. Aug. 15, 2014 - Investors Business Daily
Markets Close The Week On Negative Note As Ukraine Worries Mount 4:01 p.m. Aug. 15, 2014 - benzinga.com
U.S. Stocks Turn Lower; Dillard's Shares Slide On Downbeat Earnings 12:23 p.m. Aug. 15, 2014 - benzinga.com
Gilead Wins Sovaldi Dispute With Roche, U.K. Nod 11:23 a.m. Aug. 15, 2014 - Investors Business Daily
ACH-3102 + Sovaldi = 100% 11:03 a.m. Aug. 15, 2014 - Seeking Alpha
Markets Gain; J.C. Penney Posts Narrower-Than-Expected Q2 Loss 10:23 a.m. Aug. 15, 2014 - benzinga.com
Why Achillion Pharmaceuticals (ACHN) Stock Surged to a One-Year High Today 10:05 a.m. Aug. 15, 2014 - TheStreet.com
Stocks Hitting 52-Week Highs 9:24 a.m. Aug. 15, 2014 - benzinga.com
Morning Market Movers 8:40 a.m. Aug. 15, 2014 - benzinga.com
Top Analyst Upgrades and Downgrades: Achillion, Monster, Gilead, JCPenney, JDSU, Green Mountain and More 7:40 a.m. Aug. 15, 2014 - 247WallSt.com
Cramer's Mad Money - One Of The Highest Quality Companies In The World (8/14/14) 5:39 a.m. Aug. 15, 2014 - Seeking Alpha
Achillion Pharmaceuticals Up on Narrower-than-Expected Loss - Analyst Blog 9:10 a.m. Aug. 11, 2014 - Zacks.com
Benzinga's Top Upgrades 7:54 a.m. Aug. 11, 2014 - benzinga.com
Piper Jaffray Upgrades Achillion Pharmaceuticals To Overweight 7:19 a.m. Aug. 11, 2014 - benzinga.com
Benzinga's Top #PreMarket Gainers 7:05 a.m. Aug. 11, 2014 - benzinga.com

Achillion Achieves 100 Percent Sustained Virologic Response Rate (SVR4) From an Eight Week Phase 2 Trial Evaluating a Ribavirin-Free Regimen of ACH-3102 and Sofosbuvir for Genotype 1 HCV ("Proxy Study"

7:00 a.m. Aug. 15, 2014 - GlobeNewswire
Pre-Market Review on Biotech Equities -- Exelixis, Novavax, Achillion Pharma, XOMA, and Amicus Therapeutics 8:50 a.m. Aug. 13, 2014 - PR Newswire - PRF
Achillion Reports Second Quarter and Six Month 2014 Financial Results 4:06 p.m. Aug. 7, 2014 - GlobeNewswire
Critical Alerts For Achillion Pharmaceuticals, Synergy Resources, Invensense, JinkoSolar, and Harley-Davidson Released By InvestorsObserver 9:31 a.m. Aug. 5, 2014 - PR Newswire - PRF
Critical Alerts For Exelixis, Rocket Fuel, Netflix, Johnson & Johnson, and Achillion Pharmaceuticals Released By InvestorsObserver 9:31 a.m. July 15, 2014 - PR Newswire - PRF
Technical Data on Health Care Sector Equities -- Research on Achillion Pharma, Novavax, Dendreon, and Exelixis 7:00 a.m. July 10, 2014 - PR Newswire - PRF
Agreements, NDA Submissions, FDA Approvals, Enrollment Updates, and Index Inclusions - Analyst Notes on Jazz Pharmaceuticals, Vertex, NPS, StemCells and Achillion 5:50 a.m. July 7, 2014 - PR Newswire - PRF
Achillion Pharmaceuticals Added to the Russell 2000 and Russell Microcap Indexes 4:06 p.m. July 1, 2014 - GlobeNewswire
Critical Alerts For Bank of America, Achillion Pharmaceuticals, Walmart, SunEdison, and Advanced Micro Devices Released By InvestorsObserver 9:31 a.m. June 17, 2014 - PR Newswire - PRF
If Achillion Pharmaceuticals (NASDAQ: ACHN) Investors Are Hoping for a Buyout, This is Not an Investment Strategy; Analyst Report by BrokerBank Securities, Inc. 7:00 a.m. June 13, 2014 - PR Newswire - PRF
Technical Update, Leadership Appointments, and Clinical Trial Results - Analyst Notes on Achillion, Nektar, CytRx, Galena and Receptos 5:20 a.m. June 12, 2014 - PR Newswire - PRF
Achillion to Present at Two Upcoming Investor Conferences 6:06 a.m. June 11, 2014 - GlobeNewswire
Achillion Announces Initiation of ACH-3422 Dosing in HCV-Infected Patients and Ability to Resume Sovaprevir Clinical Program for the Treatment of Chronic HCV 6:06 a.m. June 10, 2014 - GlobeNewswire
Biotech Equities under the Scanner -- Research on Halozyme Therapeutics, Medivation, Achillion Pharma, and Alexion Pharma 8:10 a.m. June 6, 2014 - PR Newswire - PRF
Biotech Equities Under Review -- Research on Achillion Pharma, Mast Therapeutics, Alkermes, and Momenta Pharma 1:30 p.m. May 9, 2014 - PR Newswire - PRF
Achillion Reports First Quarter 2014 Financial Results 6:06 a.m. May 7, 2014 - GlobeNewswire
Achillion to Present at Three Upcoming Investor Conferences 6:31 a.m. May 1, 2014 - GlobeNewswire
Achillion Advances ACH-3422, Uridine-Analog Nucleotide Inhibitor, Into Clinical Trial; Initiates Phase 2 Pilot Study With ACH-3102, NS5A Inhibitor, for HCV 4:07 p.m. April 30, 2014 - GlobeNewswire
Biotech Stocks Review -- Research on Achillion Pharma, Medivation, Mast Therapeutics, and Athersys 8:16 a.m. April 14, 2014 - PR Newswire - PRF
Morning Analysis on Top Gainers -- Research on Achillion Pharma, Microvision, Miller Energy Resources, and Bon-Ton Stores 11:24 a.m. March 25, 2014 - PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Merit Advisors Shines as Top Energy Workplace

Well, here's something to chew on—Merit Advisors just grabbed the top spot on Hart Energy's first-ever Best Places to Work in Energy list. If you haven't heard of them, Merit's the heavyweight champ in specialty tax for the energy sector. This isn't just a shiny trophy on the shelf; it's a nod to the kind of culture that's making waves in an industry that's no stranger...

AbbVie's Bold Leap in Menstrual Migraine Treatment

AbbVie's Game-Changing Atogepant Study When it comes to pushing boundaries in the pharmaceutical world, there's no sitting on the fence. AbbVie's Phase 3 LUNA study results are painting a bright picture for women who suffer from the relentless grip of menstrual migraines. In a world where not a single treatment option has been approved specifically for this condition,...

BusyBee AI Revolutionizes Classroom Feedback Efficiency

Grading Overhaul: BusyBee's Role in Education Here's a twist for the history books: Agilix Labs' BusyBee, a slick AI assistant built right into the Buzz platform on Amazon Bedrock, is kicking traditional grading methods to the curb. This little helper is grading close to a million K-12 student submissions every month, meticulously approved by real teachers. Quite the...

Cannabis Industry Pushes for Robust Financial Services

Industry Gears Up for Financial Action Clearly, cannabis businesses are shouting louder than a vendor at a ballgame, demanding more than just the basic chips-and-soda banking service. They’re on the hunt for serious credit facilities, payments, and the traditional financial tools that most sectors take for granted. I mean, check this out: Shield Compliance just dropped...

Moore Law Investigates Aardvark Therapeutics' Risks

Moore Law Launches Probe Into Aardvark Therapeutics Nobody likes stumbling across bad news over their morning coffee, but sometimes the market loves to keep you on your toes. Now it's Aardvark Therapeutics (NASDAQ: AARD) in the headlines, and not how they'd like. This time, Moore Law PLLC is rolling up its sleeves to dig into potential misconduct by the company's top...

Navigating Land Access: The Hidden Roadblock in Mining

Mining's Often Overlooked Obstacle: Land Access In the world of mining, the shallow thrills of striking gold are often overshadowed by the frustrating slog of securing land access. You can have your permits lined up, your finances sorted, and drills humming along, but if you haven’t sweet-talked the folks farming above your visible vein of riches, you could be staring...

USFCR Wins 2026 Award for Federal Contracting Services

Award-Winning Federal Contracting Strategies News from Clearwater, Florida: US Federal Contractor Registration (USFCR) just bagged the 2026 nod from Gov Business Review as the Federal Contracting Services of the Year. Now that's a feather in the cap worth talking about. This isn't some hallway compliment, folks. It's a signal that they've nailed how to get businesses...

RTI's $14M Boost: A Game-Changer for Tech Innovators

Breaking Ground in Tech Deployment The march toward commercializing new tech can be a nightmare. Ask any innovator trying to leap from lab genius to market ready, and they'll tell you the pathway is paved with hurdles—especially in the rough-and-tumble world of energy and industrial tech. RTI International's latest $14 million move? That's a massive step in leveling the...

CrossCountry Mortgage Boosts Loan Limits, Flexibility for 2027

Trailblazing in the Mortgage Game Well, what do we have here? CrossCountry Mortgage, the big cheese of retail mortgage lenders, is cranking up their conforming loan limits to a hefty $845,000. They're jumping the gun on the Federal Housing Finance Agency's official 2027 announcement. It's a classic move—proactive, bold, and a bit of a gamble, if you ask me. They’re...

Step Inside Henson's Creature Shop Magic in NYC

Unlock Puppet Magic with Jim Henson Tours Puppet fans, let me tell you, there's something going on in Queens, NY that's got both nostalgia and innovation scribbled all over it. We're talking about the legendary Jim Henson's Creature Shop opening its doors. If you're looking to relive the magic that helped shape a generation, get ready to dive into a world where creativity...